レストレスレッグス症候群(RLS)治療薬市場:パイプライン分析・治験・特許・指定・協力・動向

P&S Market Researchが発行した調査報告書(PSM804057)
◆英語タイトル:Restless Legs Syndrome (RLS) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
◆商品コード:PSM804057
◆発行会社(リサーチ会社):P&S Market Research
◆発行日:2018年3月
◆ページ数:63
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD1,850 ⇒換算¥209,050見積依頼/購入/質問フォーム
Group License(5名様閲覧用)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,750 ⇒換算¥875,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はP&S Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。P&S Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Restless Leg Syndrome Therapeutics Pipeline in 2018
The study analyzed that the restless leg syndrome therapeutics pipeline comprises of eight drug candidates in different stages of development.

Insights on Pipeline Segments

Around 62% of the pipeline drug candidates are being developed as small molecule for the treatment of RLS. Hisamitsu Pharmaceutical Co., Inc. is in a process to conduct Phase III clinical trial on its developmental drug for the treatment of RLS. In September 2017, AXIM Biotechnologies Inc. announced that it was conducting Phase I and a proof of concept clinical trial (Phase II) of MedChew RL for treatment of RLS in Israel.

Technological Advancements Driving the Growth of RLS Therapeutics Pipeline

Various new technologies are being used by the companies for the development of drugs to treat RLS. For instance, Hisamitsu Pharmaceutical Co., Inc. is using Hisamitsu’s TDDS technology to deliver its developmental product ropinirole hydrochloride into the body through skin to maintain an adequate concentration in the blood for a long time and to avoid the first-pass effect in the liver. Alexza Pharmaceuticals Inc. is using its propriety staccato technology for the delivery of its development drug through inhalation.

Positive Clinical Trial Results Spur the Growth of RLS Therapeutics Pipeline

The drugs candidates that are being developed by the different pharmaceutical companies have demonstrated positive clinical trial results which in-turn increase their further development. For instance, In April 2017, Merz Pharma GmbH & Co KgaA announced that incobotulinumtoxin demonstrated significant improvement of RLS score in the treatment of subjects with restless leg syndrome.

Rise in Patent Approvals for RLS Therapeutics Expected to Provide Collaborative Opportunities to the Pharmaceutical Companies

It has been observed that most of the drug candidates have received or have filed for patent covering a novel mechanism for the treatment of RLS. In April 2017, Omeros Corporation announced that it owned two issued patents and one pending patent application in the U.S., and 21 issued patents and 12 pending patent applications in foreign markets directed to its discoveries linking PDE7 Program – OMS527 to movement disorders. Patent approval help in increasing opportunities for invention improvement and uniqueness.

Some of the key players developing drugs for the treatment of restless leg syndrome include Hisamitsu Pharmaceutical Co., Inc., Merz Pharma GmbH & Co KgaA, AXIM Biotechnologies Inc., and Alexza Pharmaceuticals Inc.

【レポートの目次】

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Disease Overview

4.2 Sign & Symptoms

4.3 Epidemiology

4.4 Causes

4.5 Diagnosis

4.6 Prevention and Treatment

4.7 Key Drivers

4.7.1 Driver 1

4.7.2 Driver 2

4.8 Key Barriers

4.8.1 Barrier 1

4.9 RLS Therapeutics Pipeline Analysis

4.9.1 Pipeline Analysis by Phase

4.9.2 Pipeline Analysis by Molecule Type

4.9.3 Pipeline Analysis by Route of Administration

4.9.4 Pipeline Analysis by Company

Chapter 5. RLS Therapeutics Pipeline Analysis by Phase (2018)

5.1 Phase III

5.1.1 NLS-2

5.2 Phase II

5.2.1 BP1.4979

5.2.1.1 Clinical trials

5.2.2 Xxxx

5.2.2.1 Clinical trials

5.2.2.2 Clinical trials results

5.2.3 Xxxx

5.2.3.1 Clinical trials

5.2.3.2 Strategic development

5.2.3.3 Technology

5.2.4 Xxxx

5.2.4.1 Clinical trials

5.2.4.2 Strategic development

5.2.5 Xxxx

5.2.5.1 Clinical trials

5.2.5.2 Technology

5.3 Pre-Clinical

5.3.1 OMS527

5.3.1.1 Strategic development

5.3.2 Xxxx

5.3.2.1 Clinical trials

5.3.2.2 Technology

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Player Benchmarking for RLS Therapeutics Pipeline

7.2 SWOT Analysis of RLS Therapeutics Pipeline

Chapter 8. Company Profiles

8.1 NLS Pharma Group

8.1.1 Business Overview

8.1.2 Product Offerings

8.2 Xxxx

8.2.1 Business Overview

8.2.2 Product Offerings

8.3 Xxxx

8.3.1 Business Overview

8.3.2 Product Offerings

8.4 Xxxx

8.4.1 Business Overview

8.4.2 Product Offerings

8.5 Xxxx

8.5.1 Business Overview

8.5.2 Product Offerings

8.6 Xxxx

8.6.1 Business Overview

8.6.2 Product Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

List of Tables

TABLE 1 PIPELINE ANALYSIS OF RLS THERAPEUTICS, BY COMPANY (2018)

TABLE 2 DESCRIPTION OF NLS-2

TABLE 3 DESCRIPTION OF XXXX

TABLE 4 DESCRIPTION OF XXXX

TABLE 5 CLINICAL TRIALS OF XXXX

TABLE 6 DESCRIPTION OF XXXX

TABLE 7 DESCRIPTION OF XXXX

TABLE 8 DESCRIPTION OF XXXX

TABLE 9 CLINICAL TRIALS OF XXXX

TABLE 10 DESCRIPTION OF OMS527

TABLE 11 DESCRIPTION OF XXXX

TABLE 12 NLS PHARMA GROUP – AT A GLANCE

TABLE 13 XXXX – AT A GLANCE

TABLE 14 XXXX – AT A GLANCE

TABLE 15 XXXX – AT A GLANCE

TABLE 16 XXXX – AT A GLANCE

TABLE 17 XXXX – AT A GLANCE

List of Figures

FIG 1: RESEARCH METHODOLOGY

FIG 2: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 3: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

FIG 4: RLS DRUG CANDIDATES IN DEVELOPMENT (2018)

FIG 5: RLS PIPELINE SPLIT, BY MOLECULE TYPE (2018)

FIG 6: RLS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)

FIG 7: BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 8: BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 9: KEY PLAYER BENCHMARKING

FIG 10: SWOT ANALYSIS



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ レストレスレッグス症候群(RLS)治療薬市場:パイプライン分析・治験・特許・指定・協力・動向(Restless Legs Syndrome (RLS) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆